Drug Search Results
More Filters [+]

Flucytosine

Alternative Names: flucytosine, ancobon
Latest Update: 2024-05-17
Latest Update Note: Clinical Trial Update

Product Description

Flucytosine is a medication used in the management and treatment of systemic and severe candida and cryptococcus infections. It is in the antimetabolite, antifungal class of drugs.  Flucytosine (5-FC) action takes effect when it comes in contact with the fungus and is taken up by an enzyme known as cytosine permease. (Sourced from: https://www.ncbi.nlm.nih.gov/books/NBK557607/)

Mechanisms of Action: Protein Synthesis Inhibitor,TS Inhibitor,DNA Synthesis Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Approved

Approved Countries: Australia | Austria | Brazil | China | Colombia | Czech | Dominican Republic | France | Germany | Greece | India | Ireland | Italy | Malta | Mexico | Morocco | Netherlands | New Zealand | Poland | Russia | Slovenia | South Africa | Spain | Sweden | Switzerland | Taiwan | United Kingdom | United States

Approved Indications: None

Known Adverse Events: None

Company: FORTE
Company Location: TORRANCE CA 90502
Company CEO: Dr. Paul Wagner
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Flucytosine

Countries in Clinic: United States

Active Clinical Trial Count: 2

Highest Development Phases

Phase 2: Astrocytoma|Glioblastoma|Glioma|Intestinal Cancer

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

R21CA282543

P2

Recruiting

Astrocytoma|Glioma|Glioblastoma

2034-05-01

TG6002.02

P2

Active, not recruiting

Intestinal Cancer

2021-03-12

Recent News Events